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Edited by Veli-Pekka LehtoAbstract Transforming growth factor- (TGF-), a multifunc-
tional cytokine which is involved in extracellular matrix mod-
ulation, has a major role in the pathogenesis and progression of
ﬁbrotic diseases. We now report the eﬀects of ursolic acid on
TGF-1 receptor binding and TGF-1-induced cellular functions in
vitro. Ursolic acid inhibited [125I]-TGF-1 receptor binding to
Balb/c 3T3 mouse ﬁbroblasts with an IC50 value of 6.9% 0.8
lM. Ursolic acid dose-dependently recovered reduced prolifer-
ation of Minc Mv1Lu cells in the presence of 5 nM of TGF-1 and
attenuated TGF-1-induced collagen synthesis and production in
human ﬁbroblasts. Molecular dynamics simulations suggest that
ursolic acid may interact with the hydrophobic region of the
dimeric interface and thereby inhibit the binding of TGF-1 to its
receptor. All these ﬁndings taken together show that ursolic acid
functions as an antagonist for TGF-1. This is the ﬁrst report to
show that a small molecule can inhibit TGF-1 receptor binding
and inﬂuence functions of TGF-1.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ursolic acid is a triterpenoid compound widely present in
food, medicinal herbs and other plants, and its biological ef-
fects include antitumor, hepatoprotectory, and anti-inﬂam-
matory activities [1]. In our search for active components from
the medicinal plant, Clerodendranthus spicatus (Thunb.) C.Y.
Wu, which is used as a folk medicine to treat patients with
nephritis in China, we identiﬁed ursolic acid and oleanolic acid
as compounds active against transforming growth factor-b1
(TGF-b1) receptor binding [2].
TGF-b, a key regulatory molecule in controlling the activity
of ﬁbroblasts, has been implicated in several diseases states
characterized by excess ﬁbrosis [3]. In the kidney, TGF-b
promotes tubuloepithelial cell hypertrophy and regulates glo-* Corresponding author. Fax: +81-48-652-7254.
E-mail address: shigeru.murakami@po.rd.taisho.co.jp (S. Murakami).
Abbreviations: TGF-b, transforming growth factor-b; MEM, minimal
essential medium; FBS, fetal bovine serum; Mv1Lu, mink lung
epithelial; TCA, trichloroacetic acid; DMEM, Dulbecco’s modiﬁed
essential medium
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doi:10.1016/j.febslet.2004.04.036merular production of the extracellular matrix, including col-
lagens, ﬁbronectin, and proteoglycans. TGF-b also blocks
destruction of the extracellular matrix by up-regulating the
synthesis of protease inhibitors and down-regulates the syn-
thesis of matrix-degrading proteases. Thus, TGF-b plays a
pivotal role in the pathogenesis and progression of nephritis
[4–7], as well as in ﬁbrotic changes of other tissues [8–10]. The
therapeutic beneﬁts of inhibiting TGF-b function by an anti-
body against TGF-b have been demonstrated in cases of ex-
perimental nephropathy [11,12]. Injection of decorin, a small
proteoglycan, that binds and neutralizes TGF-b1 function [13],
results in suppression of TGF-b1-induced extracellular matrix
accumulation in nephritic glomeruli [14]. Similar therapeutic
eﬀects on nephritis were noted in rats transfected with the
decorin gene [15]. While several successful approaches to in-
hibiting protein–protein binding by a small molecule have been
reported [16,17], we found no documentation concerning the
interaction of TGF-b and its receptor. We now report the
functional antagonistic eﬀects of ursolic acid in TGF-b-in-
duced inhibition of mink lung epithelial (Mv1Lu) cell prolif-
eration and TGF-b-induced production of collagen in vitro.2. Materials and methods
2.1. Materials
Recombinant human TGF-b1 was purchased from Austral Biolog-
icals (San Ramon, CA) and Genzyme Techne (Cambridge, MA). [125I]-
TGF-b1 and [3H]-thymidine were from Dupont-NEN (Boston, MA).
[2.3-3H]-proline was from Amersham (Arlington Heights, IL). EIA
Kits for procollagen type I C-peptide (PIP) were from Takara (Kyoto,
Japan). Ursolic acid, a,a0-dipyridyl and type IV collagenase were from
Sigma Chemical Co. (St. Louis, MO). Minimal essential medium
(MEM), fetal bovine serum (FBS), penicillin and streptomycin were
from Life Technologies (Rockville, MD). Other chemicals were of
analytical grade.
2.2. TGF-b1 binding assay
Binding experiments were done as described [18,19]. Brieﬂy, Balb/c
3T3 cells (Dainippon, Osaka, Japan) were seeded in a 24 well-plate at a
density of 5 104 cells per well and cultured for 3 days in MEM
supplemented with 10% FBS and antibiotics (100 IU/ml penicillin and
50 lg/ml streptomycin). When cells were at a near-conﬂuent stage, the
medium was replaced with binding buﬀer containing 50 mM Hepes,
128 mM NaCl, 5 mM KCl, 5 mM MgSO4, and 1.2 mM CaCl2. The
assay was initiated by adding 50 pM [125I]-TGF-b1 and increasing the
concentrations of ursolic acid. After 4 h at 4 C, the medium was re-
moved and cells were washed ﬁve times with ice-cold binding buﬀer.
The cells were then solubilized using buﬀer containing Triton X-100
and the radioactivity was measured. Ursolic acid was dissolved inblished by Elsevier B.V. All rights reserved.
Fig. 1. Characterization of [125I]-TGF-b1 binding to Balb/c 3T3 mouse
ﬁbroblasts. (A) Equilibrium binding of [125I]-TGF-b1 to Balb/c 3T3
mouse ﬁbroblasts. The cells were incubated in the presence of various
concentrations of [125I]-TGF-b1, as described under Section 2. Speciﬁc
binding ðÞ was estimated by subtracting the non-speciﬁc binding of
[125I]-TGF-b1 to Balb/c 3T3 mouse ﬁbroblasts ðsÞ from the total
binding ðdÞ. Data represent means obtained from measurement in
triplicate wells. (B) Scatchard analysis for the binding of [125I]-TGF-b1
to Balb/c 3T3 mouse ﬁbroblasts.
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under 0.6%. Non-speciﬁc binding was determined in the presence of an
excess (10 nM) of unlabeled TGF-b1. The IC50 value of [125I]-TGF-b1
binding inhibition by ursolic acid was determined in ﬁve separate
experiments.
2.3. Cell growth assay
Mv1Lu cells (Dainippon, Osaka, Japan) were grown and maintained
in MEM supplemented with 10% FBS, antibiotics (100 IU/ml penicillin
and 50 lg/ml streptomycin) and non-essential amino acids. For growth
inhibition assays, Mv1Lu cells were seeded at 3 104 cells/well in 24-
well plates in 500 ll/well [20]. After incubation for 1 day, medium was
replaced with fresh MEM supplemented with 0.2% FBS, maintained
for 24 h, then replaced with the same fresh medium containing the
indicated concentration of ursolic acid and 10 pM TGF-b1. Cultures
were incubated for an additional 24 h, the last 2 h being in the presence
of 0.5 lCi/ml of [3H]-thymidine. Ursolic acid was dissolved in DMSO
at a ﬁnal concentration of 1%. Cells were washed twice with phos-
phate-buﬀered saline and solubilized with 0.5 M NaOH. Incorporation
of [3H]-thymidine into DNA was measured using liquid scintillation
counting.
2.4. Measurement of collagen synthesis
The synthetic activity of collagen was assessed by incorporation of
[3H]-proline into collagenase degradable protein, as described [21,22].
Human skin ﬁbroblasts (Dainippon, Osaka, Japan) were seeded into
24-well plates at a density of 4 104 cells per well in CS-C Medium
[Dulbecco’s modiﬁed essential medium (DMEM)-HamF12 1:1] con-
taining 10% FBS, 15 mM Hepes, acidic-FGF, and heparin (Dainip-
pon, Osaka, Japan). After 24 h of serum deprivation, quiescent
medium was then replaced by 500 ll of DMEM containing 50 lg/ml b-
aminopropionitril, 50 lg/ml ascorbic acid, 10 lg/ml [3H]-proline, and 5
ng/ml TGF-b1, in the presence or absence of compounds, then the cells
were incubated for 24 h and cell layers and medium were analyzed
separately. Trichloroacetic acid (TCA)-precipitated material of incu-
bation medium was solubilized in 0.2 ml of 0.2 N NaOH. For cell
collagen assay, cells were removed and the protein-containing pellet
was solubilized in 0.2 ml of 0.2 N NaOH. After neutralization with
0.15 N HCl, 40 ll of puriﬁed collagenase solution (type IV from
Clostridium histolycum, Sigma, 1250 U/ml in 50 mM Tris–HCl, pH 7.4,
and 10 mM CaCl2) was added to each 0.46 ml sample from the me-
dium and cells and the samples were digested at 37 C for 2 h. The
samples were then reprecipitated with 10% TCA containing 0.5%
tannic acid and radioactivity released into the supernatant was deter-
mined using liquid scintillation counting. Collagenase-resistant radio-
activity in the pellet was similarly determined after solubilization in 0.2
ml of 0.2 N NaOH.
2.5. Measurement of collagen production
Production of type I collagen was estimated based on the accumu-
lation of PIP in the medium, using an enzyme immunoassay. Human
skin ﬁbroblasts (Dainippon, Osaka, Japan) were seeded into 24-well
plates at a density of 1.5 104 cells per well in CS-C Complete Me-
dium (DMEM-HamF12 1:1, Gibco) containing 10% FBS, 15 mM
Hepes, acidic-FGF, and heparin, and then grown for 48 h to reach
conﬂuency. After 24 h of serum deprivation in DMEM/F-12 medium,
quiescent medium was then replaced with fresh DMEM/F-12 con-
taining 50 lg/ml ascorbic acid and 5 ng/ml TGF-b1, in the presence or
absence of drugs. After 48 h of incubation, medium was collected by
centrifugation and PIP was determined using an enzyme immunoassay
and Takara PIP EIA Kits. Cell viability was assessed microscopically
after staining cells with Alamar Blue.
2.6. Molecular dynamics simulations
The coordinates of TGF-b and ursolic acid were taken from PDB
databank (code: 1KLC) and Cambridge Structural Database [23]
(code: TARDEV), respectively. Molecular dynamics (MD) calcula-
tions were performed under the system in which 10,362 water mole-
cules (correspond to 44 angstrom radii) were spherically attached
around the proposed complex model of TGF-b and ursolic acid. The
total number of atoms was 34 784. AMBER6 program was used for
calculations. The atomic charges of ursolic acid were calculated with
HF/6-31G* calculations and RESP ﬁtting. 1ns MD simulation was
performed using the time step of 2 fs. Temperature was controlled at
300 K during simulations and no coulomb cut-oﬀ was applied. Toaccelerate calculations, a special-purpose parallel computer for non-
bonded force sum, MD-Engine was used [24]. Total computing times
were about 11 days.
2.7. Statistical analysis
The results are expressed as mean S.E.M. Statistical signiﬁcance
was evaluated using Dunnett’s multiple comparison test.3. Results and discussion
In the present study, we obtained evidence that naturally
occurring triterpene, ursolic acid, is an inhibitor of TGF-b1
receptor binding. The fact that ursolic acid blocked TGF-b1-
induced antiproliferative activity and suppressed TGF-b1-
induced collagen production also supports antagonistic actions
of ursolic acid against TGF-b1.
In Balb/c 3T3 ﬁbroblasts, [125I]-TGF-b1 bound to the cells
with a high aﬃnity, with a Kd of 99 pM and Bmax value of 33
fmol/106 cells (Fig. 1). Under this assay condition, ursolic acid
inhibited the speciﬁc binding of [125I]-TGF-b1 to 3T3 ﬁbro-
blasts, in a dose-responsive manner with an IC50 value
(mean S.E.M.) of 6.9 0.8 lM ðn ¼ 5Þ (Fig. 2). The Ki value
(mean S.E.M.) of ursolic acid was determined to be 3.7 0.4
lM ðn ¼ 5Þ. In the previous study, to determine the speciﬁcity
Fig. 3. Eﬀect of ursolic acid on TGF-b1-induced inhibition of Mv1Lu
cell proliferation. Mv1Lu cells were incubated with TGF-b1 (10 pM)
and various concentrations of ursolic acid for 24 h, the last 2 h being in
the presence of [3H]-thymidine. The results are expressed as a per-
centage of the incorporation of [3H]-thymidine in control cells incu-
bated without TGF-b1 and ursolic acid. Each point represents the
mean of duplicate determinations performed in duplicate.
Fig. 4. Eﬀect of TGF-b1 on Mv1Lu cell proliferation in the presence of
various concentrations of ursolic acid. Mv1Lu cells were incubated
with increasing concentrations of TGF-b1 in the presence of 0 ðsÞ, 0.2
ðdÞ, 1.1 ðnÞ, 2.2 ðmÞ, and 6.6 ðÞ lM of ursolic acid for 24 h, the last 2
h being in the presence of [3H]-thymidine. The results are expressed as
a percentage of the incorporation of [3H]-thymidine in control cells
incubated without TGF-b1 and ursolic acid. Each point represents the
mean of duplicate determinations performed in duplicate.
Fig. 2. Eﬀect of ursolic acid on [125I]-TGF-b1 binding to mouse Balb/c
3T3 ﬁbroblasts. Results are expressed as percentage of speciﬁc binding
in the absence of ursolic acid. Each point represents the mean of du-
plicate determinations.
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binding of cytokines and growth factors, and activities of en-
zymes that are considered to be involved in the pathogenesis
and development of nephritis, including platelet-derived
growth factor (PDGF)-BB, tumor necrosis factor (TNF)-a,
epidermal growth factor (EGF), interleukin (IL)-6, angiotensin
II (AT1), endothelin (ETA), leukotriene B4, thromboxane A2,
platelet activating factor (PAF), and angiotensin converting
enzyme. Ursolic acid had no apparent activity to these recep-
tors and enzymes up to 10 lg/ml (6.6 lM) [2]. Therefore, in-
hibitory actions of ursolic acid are speciﬁc to TGF-b at least
among these possible factors involved in nephritis. Thus,
therapeutic eﬀects of Chinese herbal medicine, C. spicatus
(Thunb.) C.Y. Wu, on nephritis may be related to antagonistic
actions of ursolic acid and oleanolic acid against TGF-b1.
The functional eﬃcacy of ursolic acid was determined in
Mv1Lu cells. These cells are highly sensitive to the antiprolif-
erative action of TGF-b and widely used for determination of
TGF-b activity [25]. Fig. 3 shows the dose response for neu-
tralization of TGF-b1 activity by ursolic acid. Although cell
proliferation was almost completely suppressed by exoge-
nously added TGF-b1, as assessed by incorporation of
[3H]-thymidine, this compound overcame TGF-b1-induced
reduction in cell proliferation in a dose-dependent manner,
with an IC50 value of approximately 1.5 lM. Higher concen-
trations were required to cause a rightward shift in the
dose–response curve of TGF-b1-induced inhibition of cell
proliferation (Fig. 4).
In addition to proliferation of Mv1Lu cells, we made an-
other functional evaluation against TGF-b using collagen as-
say systems, since TGF-b is a potent stimulus for collagen
formation. Eﬀects of ursolic acid on collagen production were
assessed using two diﬀerent methods, measurement of [3H]-
proline incorporation into collagen in both cell layer and me-
dium and measurement of type I collagen content secreted into
the medium. TGF-b1 markedly stimulated collagen synthesis
from [3H]-proline in human ﬁbroblasts (Fig. 5). [3H]-labeled
collagen was increased by TGF-b1 more than ﬁve times in
both cell and medium. Ursolic acid (0.67–6.6 lM) dose-de-
pendently decreased [3H]-proline incorporation into collagenin both cell layer and medium. Collagen content secreted into
the medium, as measured by EIA assay, was markedly elevated
by TGF-b1 (Fig. 6). Type I collagen content in the medium
was also dose-dependently decreased by ursolic acid. Ursolic
acid up to 6.6 lM had no evident toxic action toward human
ﬁbroblasts, as assessed by cell viability assay, thus inhibitory
eﬀect of ursolic acid on collagen production was apparently
not associated with toxicity of this compound. A well-known
inhibitor of prolyl hydroxylase, a,a0-dipyridyl, at 100 lM
markedly inhibited collagen synthesis and secretion in both
assay systems. Therefore, inhibition of TGF-b1 receptor
Fig. 7. Modeling of ursolic acid bound to TGF-b1. Molecular surfaces
of the binding region are shown. Surface color deﬁnitions are as fol-
lows; red (acidic), blue (basic), green (hydrophilic), yellow (hydro-
phobic). Ursolic acid is shown as a bald stick.
Fig. 6. Eﬀect of ursolic acid on collagen production in human ﬁbro-
blasts. Conﬂuent cells were incubated with TGF-b1 (5 ng/ml) for 48 h
in the presence or absence of compounds and secretion of type I col-
lagen into the incubation medium was determined using PIP EIA kits.
Each point represents the mean of four separate determinations done
in duplicate. **P < 0:01 (vs control with TGF-b1).
Fig. 5. Eﬀect of ursolic acid on TGF-b1-stimulated collagen synthesis
in human ﬁbroblasts. Conﬂuent cells were incubated with TGF-b1 (5
ng/ml) for 24 h in the presence or absence of compounds. Incorpora-
tion of [3H]-proline into collagenase degradable protein was assessed in
the cell ðÞ and medium ðjÞ, as described under Section 2. Each bar
represents the meanS.E.M. of three separate determinations.
*P < 0:05, **P < 0:01 (vs control with TGF-b1 in the cell). ##P < 0:01
(vs control with TGF-b1 in the medium).
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and collagen production. Oleanolic acid, a structurally related
triterpenoid to ursolic acid, had similar eﬀects on TGF-b1
binding with an IC50 value of 21 lM, neutralization of Mv1Lu
cell proliferation and collagen production (data not shown).
Some traditional herbal medicines containing ursolic acid
and oleanolic acid have been used to treat subjects with hep-atitis [1]. Moreover, ursolic and oleanolic acids were reported
to be eﬀective in several animal models of liver injury [26,27].
However, the mechanism responsible for hepatoprotective
action of these triterpenes remains unclear. Based on our data,
it is plausible that preventive eﬀects of ursolic acid and ole-
anolic acid in cirrhosis and ﬁbrosis of the liver may in part be
attributed to antagonism against TGF-b, since many studies
demonstrated the important role of TGF-b in ﬁbrotic pro-
cesses of the liver [7–9], as well as the kidney.
For a detailed examination of mechanisms by which ursolic
acid inhibits the binding of TGF-b1 to its receptor, we analyzed
the interaction of ursolic acid with TGF-b1 using MD calcu-
lations, since the preliminary experiments showed that this
compound binds to TGF-b1, not the TGF-b receptor. TGF-b1
is a homologous dimeric protein containing interchain disulﬁde
bonds, and the dimeric interface region consists of the WXXD
motif (Trp52–X–X–Asp55) which is important for the growth
inhibitory activity of TGF-b1 [28], and several other solvent-
exposed hydrophobic residues such as Tyr50, Leu64, Trp28 and
Trp32. We ﬁrst analyzed the binding of ursolic acid to the
WXXD motif region. We found that the binding was unstable,
because part of the ursolic acid was dissociated with the protein
surface and wafted into the water during the simulations (data
not shown). The surface of the WXXD region is ﬂat and un-
suitable for binding of a small molecule such as ursolic acid. In
contrast, another possible binding model in which ursolic acid
binds the hydrophobic site close to theWXXDmotif was stable
during the simulations. As shown in Fig. 7, the shape and hy-
drophobicity of ursolic acid made for a good ﬁt with TGF-b1.
Our ﬁndings may account for the inhibition of receptor binding
by ursolic acid with the IC50 value of micromolar range.
Our results demonstrate that ursolic acid is an antagonist for
TGF-b1, suggesting that ursolic acid competes with TGF-b1
binding to its receptor, and thereby neutralizes anti-prolifera-
tive eﬀects of TGF-b1 and suppresses TGF-b1-induced colla-
gen production. This is the ﬁrst report to show that even this
small molecule exhibits antagonistic action against TGF-b1,
S. Murakami et al. / FEBS Letters 566 (2004) 55–59 59although macromolecules such as decorin [8,9] and peptide
antagonists [29] have been shown to antagonize TGF-b.
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